Chromogranin A expression in phaeochromocytomas associated with von hippel-lindau syndrome and multiple endocrine neoplasia type 2

Hormone and Metabolic Research

Volumn 39, Issue 12, 2007, Pages 876-883

  Cleary, S ^a,b   Phillips, J K ^a   Huynh, T T ^b   Pacak, K ^c   Fliedner, S ^c   Elkahloun, A G ^d   Munson, P ^e   Worrell, R A ^f   Eisenhofer, G ^b  

^a MURDOCH UNIVERSITY   (Australia)

^b NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^c EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^d NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^e NATIONAL INSTITUTES OF HEALTH   (United States)

^f NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Adrenaline; Catecholamines; Chromaffin cells; Exocytosis; Granin; Noradrenaline

Indexed keywords

ADRENALIN; CHROMOGRANIN A; CHROMOGRANIN B; DOPAMINE; MESSENGER RNA; NORADRENALIN;

ADOLESCENT; ADRENALIN BLOOD LEVEL; ADULT; ARTICLE; CHROMAFFIN GRANULE; CLINICAL ARTICLE; DOPAMINE BLOOD LEVEL; DOWN REGULATION; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; MALE; NORADRENALIN BLOOD LEVEL; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SCHOOL CHILD; SECRETORY VESICLE; SIPPLE SYNDROME; TISSUE LEVEL; VON HIPPEL LINDAU DISEASE;

ADOLESCENT; ADRENAL GLAND NEOPLASMS; ADULT; BLOTTING, WESTERN; CATECHOLAMINES; CHILD; CHROMOGRANIN A; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A; PHEOCHROMOCYTOMA; POLYMERASE CHAIN REACTION; REGRESSION ANALYSIS; TUMOR BURDEN; VON HIPPEL-LINDAU DISEASE;

EID: 38149131774     PISSN: 00185043     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-993135     Document Type: Article

References (33)

1. Winkler H. The composition of adrenal chromaffin granules: an assessment of controversial results. Neuroscience 1976; 1: 65-80
2. Zhang K, Rao F, Wen G, Salem RM, Vaingankar S, Mahata M, Mahapatra NR, Lillie EO, Cadman PE, Friese RS, Hamilton BA, Hook VY, Mahata SK, Taupenot L, O'Connor DT. Catecholamine storage vesicles and the metabolic syndrome: The role of the chromogranin A fragment pancreastatin. Diabetes Obes Metab 2006; 8: 621-633
3. Iacangelo AL, Eiden LE, Chromogranin A. current status as a precursor for bioactive peptides and a granulogenic/sorting factor in the regulated secretory pathway. Regul Pept 1995; 58: 65-88
4. Bonks P, Helle K. The release of protein from the stimulated adrenal medulla. Biochem J 1965; 97: 40C-41C
5. Helle KB. Some chemical and physical properties of the soluble protein fraction of bovine adrenal chromaffin granules. Mol Pharmacol 1966; 2: 298-310
6. Eiden LE, Iacangelo A, Hsu CM, Hotchkiss AJ, Bader MF, Aunis D. Chromogranin A synthesis and secretion in chromaffin cells. J Neurochem 1987; 49: 65-74
7. O'Connor DT, Frigon RP. Chromogranin A, the major catecholamine storage vesicle soluble protein. Multiple size forms, subcellular storage, and regional distribution in chromaffin and nervous tissue elucidated by radioimmunoassay. J Biol Chem 1984; 259: 3237-3247
8. Yoo SH. Coupling of the IP3 receptor/Ca2+ channel with Ca2+ storage proteins chromogranins A and B in secretory granules. Trends Neurosci 2000; 23: 424-428
9. Huttner WB, Natori S. Regulated secretion. Helper proteins for neuroendocrine secretion. Curr Biol 1995; 5: 242-245
10. Day R, Gorr SU. Secretory granule biogenesis and chromogranin A: master gene, on/off switch or assembly factor? Trends Endocrinol Metab 2003; 14: 10-13
11. Mahata SK, O'Connor DT, Mahata M, Yoo SH, Taupenot L, Wu H, Gill BM, Parmer RJ. Novel autocrine feedback control of catecholamine release. A discrete chromogranin a fragment is a noncompetitive nicotinic cholinergic antagonist. J Clin Invest 1997; 100: 1623-1633
12. Ilias I, Pacak K. Diagnosis and management of tumors of the adrenal medulla. Horm Metab Res 2005; 37: 717-721
13. Bornstein SR, Gimenez-Roqueplo AP. Genetic testing in pheochromocytoma: increasing importance for clinical decision making. Ann N Y Acad Sci 2006; 1073: 94-103
14. Eisenhofer G, Walther MM, Huynh TT, Li ST, Bornstein SR, Vortmeyer A, Mannelfi M, Goldstein DS, Linehan WM, Lenders JW, Pacak K. Pheochromocytomas in von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2 display distinct biochemical and clinical phenotypes. J Clin Endocrinol Metab 2001; 86: 1999-2008
15. Huynh TT, Pacak K, Brouwers FM, Abu-Asab MS, Worrell RA, Walther MM, Elkahloun AG, Goldstein DS, Cleary S, Eisenhofer G. Different expression of catecholamine transporters in phaeochromocytomas from patients with von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2. Eur J Endocrinol 2005; 153: 551-563
16. Eisenhofer G, Goldstein DS, Stull R, Keiser HR, Sunderland T, Murphy DL, Kopin IJ. Simultaneous liquid-chromatographic determination of 3,4-dihydroxyphenylglycol, catecholamines, and 3,4-dihydroxyphenylalanine in plasma, and their responses to inhibition of monoamine oxidase. Clin Chem 1986; 32: 2030-2033
17. Cleary S, Brouwers FM, Eisenhofer G, Pacak K, Christie DL, Lipski J, MacNeil AR, Phillips JK. Expression of the Noradrenaline Transporter (NAT) and Phenylethanolamine N-Methyltransferase (PNMT) in Normal Human Adrenal Gland and Phaeochromocytoma. Cell Tissue Res 2005; 322: 443-453
18. Ehrhart-Bornstein M, Breidert M, Guadanucci P, Wozniak W, Bocian-Sobkowska J, Malendowicz LK, Bornstein SR. 17 alpha-hydroxylase and chromogranin A in 6th week human fetal adrenals. Horm Metab Res 1997; 29: 30-32
19. Eisenhofer G, Lenders JW, Linehan WM, Walther MM, Goldstein DS, Keiser HR. Plasma normetanephrine and metanephrine for detecting pheochromocytoma in von Hippel-Lindau disease and multiple endocrine neoplasia type 2. N Engl J Med 1999; 340: 1872-1979
20. Brouwers FM, Gläsker S, Nave AF, Vortmeyer AO, Lubensky I, Huang S, Abu-Asab MS, Eisenhofer G, Weil RJ, Park DM, Linehan WM, Pacak K, Zhuang Z. Proteomic profiling of VHL and MEN 2 pheochromocytomas reveals different expression of chromogranin B. Endocr Relat Cancer 2007, in press
21. Cleary S, Phillips JK, Huynh T-T, Pacak K, Elkahloun AG, Barb J, Worrell RA, Goldstein DS, Eisenhofer G. Neuropeptide Y expression in phaeochromocytomas: relative absence in tumours from patients with von Hippel-Lindau syndrome. J Endocrinol 2007; 193: 225-233
22. Kim T, Zhang CF, Sun Z, Wu H, Loh YP. Chromogranin A deficiency in transgenic mice leads to aberrant chromaffin granule biogenesis. J Neurosci 2005; 25: 6958-6961
23. Mahapatra NR, O'Connor DT, Vaingankar SM, Hikim AP, Mahata M, Ray S, Staite E, Wu H, Gu Y, Dalton N, Kennedy BP, Ziegter MG, Ross J, Mahata SK. Hypertension from targeted ablation of chromogranin A can be rescued by the human ortholog. J Clin Invest 2005; 115: 1942-1952
24. Kim T, Tao-Cheng JH, Eiden LE, Loh YP. Chromogranin A, an "on/off" switch controlling dense-core secretory granule biogenesis. Cell 2001; 106: 499-509
25. Courel M, Rodemer C, Nguyen ST, Pance A, Jackson AP, O'Connor DT, Taupenot L. Secretory granule biogenesis in sympathoadrenal cells: identification of a granulogenic determinant in the secretory prohormone chromogranin A. J Biol Chem 2006; 281: 38038-38051
26. Taupenor L, Harper KL, O'Connor DT. Role of H+-ATPase-mediated acidification in sorting and release of the regulated secretory protein chromogranin A: evidence for a vesiculogenic function. J Biol Chem 2005;280:3885-3897
27. Huh YH, Jeon SH, Yoo SH. Chromogranin B-induced secretory granule biogenesis: comparison with the similar role of chromogranin A. J Biol Chem 2003; 278: 40581-40589
28. Hendy GN, Li T, Girard M, Feldstein RC, Malay S, Desjardins R, Day R, Karaplis AC, Tremblay ML, Canaff L. Targeted ablation of the chromogranin a (Chga) gene: normal neuroendocrine dense-core secretory granules and increased expression of other granins. Mol Endocrinol 2006; 20: 1935-1947
29. Tischler AS, Kimura N, MacNicol AM. Pathology of pheochromocytoma and extra-adrenal paraganglioma. Ann N Y Acad Sci 2006; 1073: 557-570
30. Mahata SK, Mahata M, Wakade AR, O'Connor DT. Primary structure and function of the catecholamine release inhibitory peptide catestatin (chromogranin A(344-364)): identification of amino acid residues crucial for activity. Mol Endocrinol 2000; 14: 1525-1535
31. Bruce AW, Krejci A, Ooi L, Deuchars J, Wood IC, Dolezal V, Buckley NJ. The transcriptional repressor REST is a critical regulator of the neurosecretory phenotype. J Neurochem 2006; 98: 1828-1840
32. Huynh TT, Pacak K, Wong DL, Linehan WM, Goldstein DS, Elkahloun AG, Munson PJ, Eisenhofer G. Transcriptional regulation of phenylethanolamine N-methyltransferase in pheochromocytomas from patients with von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2. Ann N Y Acad Sci 2006; 1073: 241-252
33. Eisenhofer G, Huynh TT, Pacak K, Brouwers FM, Walther MM, Linehan WM, Munson PJ, Mannelli M, Goldstein DS, Elkahloun AG. Distinct gene expression profiles in norepinephrine- and epinephrine-producing hereditary and sporadic pheochromocytomas: activation of hypoxia-driven angiogenic pathways in von Hippel-Lindau syndrome. Endocr Relat Cancer 2004; 11: 897-911